medigraphic.com
ISSN 1727-897X (Electronic)

2022, Number 3

<< Back Next >>

Medisur 2022; 20 (3)

Correlation between cognitive status and tomographic findings in patients with neurocysticercosis. Ecuador, 2019 - 2020

Anaya GJL, López-Muñoz F, Carmona Alvarez-Builla E, Miniet CAE

Language: Spanish
References: 26
Page: 409-419
PDF size: 510.87 Kb.


ABSTRACT

Background: Many patients with neurocysticercosis manifest cognitive damage, with important effects on their quality of life.
Objective: to determine the correlation between cognitive status and tomographic findings in patients with neurocysticercosis.
Method: correlational, prospective and cross-sectional study, which included 93 patients diagnosed with neurocysticercosis treated in two Ecuadorian hospitals, from May 2019 to May 2020. The Folstein Mini-Mental State Examination was used for cognitive assessment. The relative risk and the Chi square test were estimated, considering statistical significance if p<0.05. For the multivariate analysis, a binary logistic regression model was used.
Results: among the tomographic findings, lesions greater than 1 cm (32.2%), multiple (30.1%), located in the parietal region (34.4%) and subarachnoid (46.2%) enhance. The cognitive evaluation showed normal results in 74.2% of the cases, as well as mild to moderate dementia in 9.7% of the patients. The most affected area was the language (54.8%). Dementia was mainly associated with lesion size greater than 1 centimeter [RR: 7.35; 95% CI: 1.62-33.3], followed by the number of lesions (multiple or racemose) and the mixed topography. In the multivariate analysis, these lost the correlation.
Conclusion: The cognitive deficit had a lower prevalence than that described in the specialized literature, and was associated with tomographic variables such as the size, number and location of the lesions; in multivariate analysis, none of these factors maintained their statistical significance.


REFERENCES

  1. Garcia HH, Gonzalez AE, Gilman RH. Taenia solium cysticercosis and its impact in neurological disease. Clin Microbiol Rev. 2020;33(3):e00085-19.

  2. Huang X, Wang Z, Kou J, Liu H, Mao D, Yu Z, et al. A Large Cohort of Neurocysticercosis in Shandong Province, Eastern China, 1997-2015.Vector Borne Zoonotic Dis. 2019;19(12):901-907.

  3. Carpio A, Fleury A, Allen Hauser W. Neurocysticercosis five new things. Neurol Clin Pract. 2013;3(2):118-25.

  4. Ramirez J, Higuera J, Espinola M, Corona T. Neuropsychiatric disorders in patients with neurocysticercosis. Asia Pac Psychiatry. 2017;9(2):e12250.

  5. Garcia C. Changes in Personality Caused by Neurocysticercosis. Psychology[Internet]. 2016 Jan 5 [cited 2021 Jun 17];7-18p.

  6. Kalra H, Allet L, Tiwari SC, Janca A. Psychiatric manifestations of neurocysticercosis. Psychiatr Danub. 2006;18( 4):200-4.

  7. El-Kady AM, Allemailem KS, Almatroudi A, Abler B, Elsayed M. Psychiatric Disorders of Neurocysticercosis: Narrative Review. Neuropsychiatr Dis Treat. 2021;17(2):1599-610.

  8. Jácome EC, Correa EP, Martinez B, Ortiz MA, García MA. Neurocysticercosis a public health problem. Clin Case Reports. 2017;5(4):543-4.

  9. Del Brutto OH, Nash TE, White AC, Rajshekhar V, Wilkins PP, Singh G, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017;372(2):202-10.

  10. Folstein MF, Folstein SE, McHugh PR. J Psychiatr Res. 1975;12(3):189-98.

  11. Aparicio E, Pérez D, García A. Validación del MMSE de Folstein en una población española de bajo nivel educativo. Rev Esp Geriatr Gerontol[Internet]. 1998[citado 17/06/2021];34(6):[aprox. 20p]. Disponible en: https://www.elsevier.es/es-revista-revista-espanola-geriatria-gerontologia-124-articulo-validacion-del-mmse-folstein-una-1301168511.

  12. Reyes S, Beaman P, Garcia C, Villa M, Heres J, Córdova A, et al. Validation of a modified version of the Mini-Mental State Examination (MMSE) in Spanish. Aging, Neuropsychol Cogn[Internet]. 2004[citado 17/06/2021];11(1):[aprox. 20p]. Disponible en: https://www.tandfonline.com/doi/abs/10.1076/anec.11.1.1.2936612.

  13. Del Brutto OH, Issa NP, Salgado P, Del Brutto VJ, Zambrano M, Lama J, et al. The association between neurocysticercosis and hippocampal atrophy is related to age. Am J Trop Med Hyg. 2017;96(1):243-8.

  14. Ballón B, Jiménez FEL, Vásquez JJA. Clinical characteristics of neurocysticercosis from a reference hospital of the northern of peru. 2016-2018. Rev Chilena Infectol. 2020;37(6):690-3.

  15. Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol. 2011;7(10):584-94.

  16. Mahale RR, Mehta A, Rangasetty S. Extraparenchymal (Racemose) Neurocysticercosis and Its Multitude Manifestations: A Comprehensive Review. J Clin Neurol. 2015;11(3):203-11.

  17. Singhi P, Malhi P, Suthar R, Deo B, Khandelwal NK. Long-term Cognitive Outcome of Children With Parenchymal Neurocysticercosis: A Prospective Observation Study. J Child Neurol. 2018;33(7):468-73.

  18. Nikoli S, Cvetkovi D, Živkovi V. Cysticercosis and suicide - an example from a forensic collection. Forensic Sci Med Pathol. 2021;17(1):167-71.

  19. Kurz C, Schmidt V, Poppert H, Wilkins P, Noh J, Poppert S, et al. Case report: An unusual presentation of neurocysticercosis: A space-occupying lesion in the fourth ventricle associated with progressive cognitive decline. Am J Trop Med Hyg. 2016;94(1):172-5.

  20. Carabin H, Ndimubanzi PC, Budke CM, Nguyen H, Qian Y, Cowan LD, et al. Clinical manifestations associated with neurocysticercosis: A systematic review. PLoS Negl Trop Dis. 2011;5(5):e1152.

  21. Forlenza OV, Vieira Filho AHG, Nobrega JPS, Dos Ramos L, De Barros NG, De Camargo CHP, et al. Psychiatric manifestations of neurocysticercosis: A study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry. 1997;62(6):612-6.

  22. Ciampi de Andrade D, Rodrigues CL, Abraham R, Castro LHM, Livramento JA, Machado LR, et al. Cognitive impairment and dementia in neurocysticercosis: A cross-sectional controlled study. Neurology. 2010;74(16):1288-95.

  23. Rodrigues CL, De Andrade DC, Livramento JA, Machado LR, Abraham R, Massaroppe L, et al. Spectrum of cognitive impairment in neurocysticercosis Differences according to disease phase. Neurology. 2012;78(12):861-6.

  24. Saini AG, Vyas S, Singhi P. Racemose neurocysticercosis. J Infect Public Health. 2017;10(6):884-5.

  25. Varghese V, Chandra SR, Christopher R, Rajeswaran J, Prasad C, Subasree R, et al. Cognitive dysfunction and its determinants in patients with neurocysticercosis. Indian J Psychol Med. 2016;38(2):142-6.

  26. Del Brutto OH, Engel J, Eliashiv DS, García HH. Update on Cysticercosis Epileptogenesis: the Role of the Hippocampus. Curr Neurol Neurosci Rep[Internet]. 2016[citado 17/06/2021];16(1):[aprox. 24p




2020     |     www.medigraphic.com